胃癌治療薬の世界市場レポート、歴史と予測2018-2029年、企業別、主要地域別、タイプ別、用途別内訳データGlobal Gastric Carcinomas Drugs Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application 胃癌は胃粘膜の癌である。初期症状として、胸やけ、上腹部痛、吐き気、食欲不振などがある。症状は消化性潰瘍と類似しているため、治療が遅れ、死亡率が高い。 QYResearch発行の胃癌治療薬に関する調査レポート... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー胃癌は胃粘膜の癌である。初期症状として、胸やけ、上腹部痛、吐き気、食欲不振などがある。症状は消化性潰瘍と類似しているため、治療が遅れ、死亡率が高い。QYResearch発行の胃癌治療薬に関する調査レポートは、2022年にCOVID-19とロシア・ウクライナ戦争が市場に影響を与えることを明らかにしている。胃癌治療薬の世界市場は、2023年から2029年の間に年平均成長率%で、2022年の100万米ドルから増加し、2029年には100万米ドルに達すると予測されています。病院と診療所からの需要が業界の主要な推進力である。 世界の医薬品市場は、2022年には1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的医薬品が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。 レポートの範囲 本レポートは、過去の分析(2018-2022年)と予測計算(2023-2029年)に基づき、読者が世界の胃癌治療薬市場を多角的に包括的に理解することを目的とし、読者の戦略と意思決定に十分なサポートを提供します。 本レポートに掲載されている企業、タイプ、用途、地域 企業別 ファイザー ノボノルディスク バイエル メルク社 ロシュ イーライリリー・アンド・カンパニー 大鵬薬品工業 江蘇恒瑞医薬有限公司 福建海王福耀薬業有限公司 斉魯薬業 山東新時代ホテル医薬工業有限公司 嘉泰天青 タイプ別セグメント ファーストライン治療 セカンドライン治療 スリーライン治療 用途別セグメント 病院 クリニック その他 地域別 北米 アメリカ カナダ 欧州 ドイツ フランス 英国 イタリア ロシア 北欧諸国 アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア ラテンアメリカ メキシコ ブラジル 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 本レポートの各章は、読者が胃癌治療薬市場をさらに理解するための詳細情報を提供しています: 第1章:歴史と予測期間(2018-2023年、2024-2029年)における世界と地域の市場規模とCAGR。 第2章:2018年から2023年までの北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカにおける各タイプの製品タイプと収益分析。 第3章:2018年から2023年までの北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカにおける製品用途と各用途の収益分析。 第4章:企業競争状況、製品名企業の競争状況、収益、市場シェアとランキング、最新の開発計画、合併、買収情報などの詳細分析。 第5章:企業概要:企業の基本情報、胃がん治療薬の紹介などをカバーする。各企業の胃がん治療薬の売上高と売上総利益率、最近の開発状況もこの部分に含まれています。 第6章から第10章:北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカの国別レベル分析(収益別)。 第11章:市場力学、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク。 第12章:包括的調査に基づく胃癌治療薬市場に関するQYResearch社の結論 第13章:QYResearchが採用した方法論とデータソース。 目次1 Market Overview of Gastric Carcinomas Drugs1.1 Gastric Carcinomas Drugs Market Overview 1.1.1 Gastric Carcinomas Drugs Product Scope 1.1.2 Gastric Carcinomas Drugs Market Status and Outlook 1.2 Global Gastric Carcinomas Drugs Market Size Overview by Region 2018 VS 2022 VS 2029 1.3 Global Gastric Carcinomas Drugs Market Size by Region (2018-2029) 1.4 Global Gastric Carcinomas Drugs Historic Market Size by Region (2018-2023) 1.5 Global Gastric Carcinomas Drugs Market Size Forecast by Region (2024-2029) 1.6 Key Regions, Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.1 North America Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.2 Europe Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.3 Asia-Pacific Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.4 Latin America Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.5 Middle East & Africa Gastric Carcinomas Drugs Market Size (2018-2029) 2 Gastric Carcinomas Drugs Market by Type 2.1 Introduction 2.1.1 First Line Treatment 2.1.2 Second Line Treatment 2.1.3 Three Line Treatment 2.2 Global Gastric Carcinomas Drugs Market Size by Type: 2018 VS 2022 VS 2029 2.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Type (2018-2023) 2.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2024-2029) 2.3 Key Regions Market Size by Type 2.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 3 Gastric Carcinomas Drugs Market Overview by Application 3.1 Introduction 3.1.1 Hospital 3.1.2 Clinic 3.1.3 Others 3.2 Global Gastric Carcinomas Drugs Market Size by Application: 2018 VS 2022 VS 2029 3.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Application (2018-2023) 3.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2024-2029) 3.3 Key Regions Market Size by Application 3.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 4 Gastric Carcinomas Drugs Competition Analysis by Players 4.1 Global Gastric Carcinomas Drugs Market Size by Players (2018-2023) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2022) 4.3 Date of Key Players Enter into Gastric Carcinomas Drugs Market 4.4 Global Top Players Gastric Carcinomas Drugs Headquarters and Area Served 4.5 Key Players Gastric Carcinomas Drugs Product Solution and Service 4.6 Competitive Status 4.6.1 Gastric Carcinomas Drugs Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles 5.1 Pfizer 5.1.1 Pfizer Profile 5.1.2 Pfizer Main Business 5.1.3 Pfizer Gastric Carcinomas Drugs Products, Services and Solutions 5.1.4 Pfizer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.1.5 Pfizer Recent Developments 5.2 Novo Nordisk 5.2.1 Novo Nordisk Profile 5.2.2 Novo Nordisk Main Business 5.2.3 Novo Nordisk Gastric Carcinomas Drugs Products, Services and Solutions 5.2.4 Novo Nordisk Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.2.5 Novo Nordisk Recent Developments 5.3 Bayer 5.3.1 Bayer Profile 5.3.2 Bayer Main Business 5.3.3 Bayer Gastric Carcinomas Drugs Products, Services and Solutions 5.3.4 Bayer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.3.5 Merck & Co Recent Developments 5.4 Merck & Co 5.4.1 Merck & Co Profile 5.4.2 Merck & Co Main Business 5.4.3 Merck & Co Gastric Carcinomas Drugs Products, Services and Solutions 5.4.4 Merck & Co Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.4.5 Merck & Co Recent Developments 5.5 Roche 5.5.1 Roche Profile 5.5.2 Roche Main Business 5.5.3 Roche Gastric Carcinomas Drugs Products, Services and Solutions 5.5.4 Roche Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.5.5 Roche Recent Developments 5.6 Eli Lilly and Company 5.6.1 Eli Lilly and Company Profile 5.6.2 Eli Lilly and Company Main Business 5.6.3 Eli Lilly and Company Gastric Carcinomas Drugs Products, Services and Solutions 5.6.4 Eli Lilly and Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.6.5 Eli Lilly and Company Recent Developments 5.7 Taiho Pharmaceutical 5.7.1 Taiho Pharmaceutical Profile 5.7.2 Taiho Pharmaceutical Main Business 5.7.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Products, Services and Solutions 5.7.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.7.5 Taiho Pharmaceutical Recent Developments 5.8 Jiangsu Hengrui Medicine Company Limited 5.8.1 Jiangsu Hengrui Medicine Company Limited Profile 5.8.2 Jiangsu Hengrui Medicine Company Limited Main Business 5.8.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Products, Services and Solutions 5.8.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.8.5 Jiangsu Hengrui Medicine Company Limited Recent Developments 5.9 Fujian Haiwang Fuyao Pharmacy Limited Company 5.9.1 Fujian Haiwang Fuyao Pharmacy Limited Company Profile 5.9.2 Fujian Haiwang Fuyao Pharmacy Limited Company Main Business 5.9.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Products, Services and Solutions 5.9.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.9.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments 5.10 Qilu Pharma 5.10.1 Qilu Pharma Profile 5.10.2 Qilu Pharma Main Business 5.10.3 Qilu Pharma Gastric Carcinomas Drugs Products, Services and Solutions 5.10.4 Qilu Pharma Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.10.5 Qilu Pharma Recent Developments 5.11 Shandong New Era Hotel Pharmaceutical Industry Limited Company 5.11.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Profile 5.11.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Main Business 5.11.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Products, Services and Solutions 5.11.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.11.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments 5.12 Chiatai Tianqing 5.12.1 Chiatai Tianqing Profile 5.12.2 Chiatai Tianqing Main Business 5.12.3 Chiatai Tianqing Gastric Carcinomas Drugs Products, Services and Solutions 5.12.4 Chiatai Tianqing Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.12.5 Chiatai Tianqing Recent Developments 6 North America 6.1 North America Gastric Carcinomas Drugs Market Size by Country (2018-2029) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Gastric Carcinomas Drugs Market Size by Country (2018-2029) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic Countries 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2018-2029) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Gastric Carcinomas Drugs Market Size by Country (2018-2029) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2018-2029) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Gastric Carcinomas Drugs Market Dynamics 11.1 Gastric Carcinomas Drugs Industry Trends 11.2 Gastric Carcinomas Drugs Market Drivers 11.3 Gastric Carcinomas Drugs Market Challenges 11.4 Gastric Carcinomas Drugs Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List
SummaryGastric Carcinomas is a cancer of the gastric mucosa. Early symptoms include heartburn, upper abdominal pain, nausea, and loss of appetite. Symptoms are similar to those of peptic ulcers, leading to delayed treatment and a high mortality rate. Table of Contents1 Market Overview of Gastric Carcinomas Drugs1.1 Gastric Carcinomas Drugs Market Overview 1.1.1 Gastric Carcinomas Drugs Product Scope 1.1.2 Gastric Carcinomas Drugs Market Status and Outlook 1.2 Global Gastric Carcinomas Drugs Market Size Overview by Region 2018 VS 2022 VS 2029 1.3 Global Gastric Carcinomas Drugs Market Size by Region (2018-2029) 1.4 Global Gastric Carcinomas Drugs Historic Market Size by Region (2018-2023) 1.5 Global Gastric Carcinomas Drugs Market Size Forecast by Region (2024-2029) 1.6 Key Regions, Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.1 North America Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.2 Europe Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.3 Asia-Pacific Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.4 Latin America Gastric Carcinomas Drugs Market Size (2018-2029) 1.6.5 Middle East & Africa Gastric Carcinomas Drugs Market Size (2018-2029) 2 Gastric Carcinomas Drugs Market by Type 2.1 Introduction 2.1.1 First Line Treatment 2.1.2 Second Line Treatment 2.1.3 Three Line Treatment 2.2 Global Gastric Carcinomas Drugs Market Size by Type: 2018 VS 2022 VS 2029 2.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Type (2018-2023) 2.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2024-2029) 2.3 Key Regions Market Size by Type 2.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 2.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029) 3 Gastric Carcinomas Drugs Market Overview by Application 3.1 Introduction 3.1.1 Hospital 3.1.2 Clinic 3.1.3 Others 3.2 Global Gastric Carcinomas Drugs Market Size by Application: 2018 VS 2022 VS 2029 3.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Application (2018-2023) 3.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2024-2029) 3.3 Key Regions Market Size by Application 3.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 3.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029) 4 Gastric Carcinomas Drugs Competition Analysis by Players 4.1 Global Gastric Carcinomas Drugs Market Size by Players (2018-2023) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2022) 4.3 Date of Key Players Enter into Gastric Carcinomas Drugs Market 4.4 Global Top Players Gastric Carcinomas Drugs Headquarters and Area Served 4.5 Key Players Gastric Carcinomas Drugs Product Solution and Service 4.6 Competitive Status 4.6.1 Gastric Carcinomas Drugs Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles 5.1 Pfizer 5.1.1 Pfizer Profile 5.1.2 Pfizer Main Business 5.1.3 Pfizer Gastric Carcinomas Drugs Products, Services and Solutions 5.1.4 Pfizer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.1.5 Pfizer Recent Developments 5.2 Novo Nordisk 5.2.1 Novo Nordisk Profile 5.2.2 Novo Nordisk Main Business 5.2.3 Novo Nordisk Gastric Carcinomas Drugs Products, Services and Solutions 5.2.4 Novo Nordisk Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.2.5 Novo Nordisk Recent Developments 5.3 Bayer 5.3.1 Bayer Profile 5.3.2 Bayer Main Business 5.3.3 Bayer Gastric Carcinomas Drugs Products, Services and Solutions 5.3.4 Bayer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.3.5 Merck & Co Recent Developments 5.4 Merck & Co 5.4.1 Merck & Co Profile 5.4.2 Merck & Co Main Business 5.4.3 Merck & Co Gastric Carcinomas Drugs Products, Services and Solutions 5.4.4 Merck & Co Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.4.5 Merck & Co Recent Developments 5.5 Roche 5.5.1 Roche Profile 5.5.2 Roche Main Business 5.5.3 Roche Gastric Carcinomas Drugs Products, Services and Solutions 5.5.4 Roche Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.5.5 Roche Recent Developments 5.6 Eli Lilly and Company 5.6.1 Eli Lilly and Company Profile 5.6.2 Eli Lilly and Company Main Business 5.6.3 Eli Lilly and Company Gastric Carcinomas Drugs Products, Services and Solutions 5.6.4 Eli Lilly and Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.6.5 Eli Lilly and Company Recent Developments 5.7 Taiho Pharmaceutical 5.7.1 Taiho Pharmaceutical Profile 5.7.2 Taiho Pharmaceutical Main Business 5.7.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Products, Services and Solutions 5.7.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.7.5 Taiho Pharmaceutical Recent Developments 5.8 Jiangsu Hengrui Medicine Company Limited 5.8.1 Jiangsu Hengrui Medicine Company Limited Profile 5.8.2 Jiangsu Hengrui Medicine Company Limited Main Business 5.8.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Products, Services and Solutions 5.8.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.8.5 Jiangsu Hengrui Medicine Company Limited Recent Developments 5.9 Fujian Haiwang Fuyao Pharmacy Limited Company 5.9.1 Fujian Haiwang Fuyao Pharmacy Limited Company Profile 5.9.2 Fujian Haiwang Fuyao Pharmacy Limited Company Main Business 5.9.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Products, Services and Solutions 5.9.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.9.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments 5.10 Qilu Pharma 5.10.1 Qilu Pharma Profile 5.10.2 Qilu Pharma Main Business 5.10.3 Qilu Pharma Gastric Carcinomas Drugs Products, Services and Solutions 5.10.4 Qilu Pharma Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.10.5 Qilu Pharma Recent Developments 5.11 Shandong New Era Hotel Pharmaceutical Industry Limited Company 5.11.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Profile 5.11.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Main Business 5.11.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Products, Services and Solutions 5.11.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.11.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments 5.12 Chiatai Tianqing 5.12.1 Chiatai Tianqing Profile 5.12.2 Chiatai Tianqing Main Business 5.12.3 Chiatai Tianqing Gastric Carcinomas Drugs Products, Services and Solutions 5.12.4 Chiatai Tianqing Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023) 5.12.5 Chiatai Tianqing Recent Developments 6 North America 6.1 North America Gastric Carcinomas Drugs Market Size by Country (2018-2029) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Gastric Carcinomas Drugs Market Size by Country (2018-2029) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic Countries 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2018-2029) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Gastric Carcinomas Drugs Market Size by Country (2018-2029) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2018-2029) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Gastric Carcinomas Drugs Market Dynamics 11.1 Gastric Carcinomas Drugs Industry Trends 11.2 Gastric Carcinomas Drugs Market Drivers 11.3 Gastric Carcinomas Drugs Market Challenges 11.4 Gastric Carcinomas Drugs Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(データ解析)の最新刊レポートQYResearch 社の最新刊レポート本レポートと同じKEY WORD(breakdown data)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/04 10:27 147.72 円 163.39 円 196.69 円 |